Chai Discovery, which builds frontier artificial intelligence to predict and reprogram the interactions between biochemical ...

Galapagos named former Horizon Therapeutics exec Aaron Cox as CFO. Saatchi & Saatchi Wellness, a 2025 MM+M Agency 100 honoree, named Brendan Gallagher as president, Beth Bour as chief client officer ...

Arbor Biotechnologies Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors. Former Pfizer Chief Scientific Officer brings decades of drug development and strategic leadership experience to ...

Incyte’s Hervé Hoppenot is hanging up his hat after spending more than a decade building the company into the ...

Pfizer’s Debt figure was $61 Bil at the end of the most recent quarter, while its market capitalization is $133 Bil (as of 6/2/2025). This implies a poor Debt-to-Equity Ratio of 46.2% (vs. 19.9% ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s move for a lot less money.

Recent research has linked Pfizer's widely-used Depo-Provera birth control shot to massively increased risk of developing brain tumors — and hundreds of women are suing the pharmaceutical giant ...

The past three years have been challenging for Pfizer (PFE 1.14%). Revenue and earnings have moved in the wrong direction, as has the company's share price. The stock is down by 56% since 2022.

Lately, Pfizer (PFE-0.08%) and Prologis (PLD-0.32%) have been perfect examples of the trade-off between attractive yields and dividend growth. Pfizer offers a sky-high yield that's climbing slowly.

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Offi ...

Pfizer appears to be a very promising stock to buy if you're looking for income. That 7.3% dividend yield is terrific, and even if it gets slashed, it will likely still be substantial.